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age of ten years. The following years symptoms worsened and she 
developed headaches, depressive thoughts with catatonic as well 
as obsessive-compulsive and psychotic behaviour with multiple 
suicidal attempatients. Laboratory investigations revealed leuco- 
and thrombopenia, as well as a positive ANF, with anti-ENA RNP-a, 
RNP 70-k and RNP-c, suggestive for an auto-immune disorder. MRI 
of the brain was normal, but EEG was abnormal and the skin biopsy 
revealed IgG-deposition along the basal membrane. Initial treatment 
with corticoids and hydroxychloroquine resulted in improvement. 
However, after three months symptoms worsened and were resistant 
to subsequent treatment (Corticoids, low dose cyclophosphamide, 
plasmapheresis and anti- CD20 monoclonal antibodies). Finally, an 
ASCT according to the EBMT- ASTIL guidelines was performed. PBSC 
harvest was done after Cyclophosphamide (2X2g/m).The conditioning 
regimen consisted of cyclophosphamide 200 mg/kg and ATG 7.5 
mg/kg. There were no severe problems with the conditioning 
regimen. The ASCT resulted in a spectacular improvement of the 
neuropsychiatric disabilities of this patient.
Discussion
Patients with NPSLE who are refractory to conventional treatment 
can achieve clinical remission after ASCT. This improvement is due 
to immunological changes that can not be achieved with other 
treatments. Patients should be considered for ASCT if a) they are 
resistant to first line treatment b) there is a high mortality risk due 
to de NPSLE, in this case suicidal attempatients c) ASCT should be 
performed before irreversible organ damage has occurred. 
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Background 
Thymosin alpha 1 (Ta1) is a thymic peptide with known immuno-
modulating properties, including increase of immune reconstitution 
after stem cell transplantation (SCT), enhancement of anti-tumour 
responses and direct effects on cancer cells (up-regulation of MHC-I 
expression, decrease of proliferation). We thus wanted to study the 
effects of Ta1 on murine models of multiple myeloma (MM) and 
immune reconstitution after SCT.
Methods and results 
We first studied the in vitro effects of Ta1 on two murine MM cell 
lines, MOPC315.BM (Balb/c background) and 5TGM1 cells (C57Bl/
KalwRij background). No significant effect of Ta1 has been observed 
on MHC-I/II up-regulation (flow cytometry), viability (MTT tests) or 
proliferation (3H-thymidin incorporation) of these cells. Since anti-
tumour responses are complex and difficult to transpose in vitro, 
we studied the in vivo effects of Ta1 in the MM models. Mice were 
intravenously injected with 2.5x10^5 MM cells and treated daily by 
subcutaneous injections with 0.4 mg/kg Ta1 or PBS. MM development 
was evaluated by bone marrow and spleen infiltration at sacrifice, 
and paraprotein quantitation. No significant, recurrent effect of 
Ta1 was seen on MM development. Moreover, no significant effect 
of Ta1 could be observed on solid tumour growth (subcutaneous 
injection of MOPC315.BM cells). Finally, we studied the effects of 
Ta1 on immune reconstitution in a humanized murine model using 
immunodeficient NSG mice, transplanted with 5x10^5 human 
hematopoietic stem cells (AC133). Immune cell reconstitution was 
studied by flow cytometry on blood samples and at sacrifice (105 
days post-transplantation). No significant effect of Ta1 could be 
seen on immune reconstitution in this model.
Conclusions 
No biological effects of Ta1 could be observed on MM development 
or immune reconstitution in the proposed murine models, in 
contradiction with the immunomodulatory properties attributed 
to this peptide in the literature.
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Background
Rothmund-Thomson (RTS) syndrome is a rare autosomal recessively 
inherited genodermatosis. It is characterized by poikiloderma, 
small stature, skeletal and dental abnormalities, cataract, and an 
increased risk of cancer. The syndrome is caused by mutations in 
RECQL4 at 8q24.
Aims
To describe the osseous and immunologic features of three patients 
with genetically confirmed RTS.
Methods
Immunological investigation, x-ray imaging and bone densitometry 
were performed at time of the first visit to the combined 
rheumatology-immunology clinic.
Results
All patients had characteristic poikiloderma as well as thumb 
anomalies. They were born dysmaturely and presented with failure 
to thrive. Age at genetic diagnosis was 5y, 4y and 3y for P1, P2, P3. 
Osteopenia and abnormal metaphyseal trabeculation of bones 
were striking on the initial skeletal survey in all patients. Z-scores 
on DXA scan were -0.1, -1.1 and -1.2 for P1, P2, P3 respectively at 
presentation. The presentation in P2 was dramatic with six fractures 
in upper and lower extremities and subluxation of both radii.
All patients were suffering from recurrent chest infections. P1 had 
granulomatous skin inflammation following primo VZV infection. 
All patients have low switched memory B cells for age, P1 has IgG2 
deficiency. P1 and P3 have IgM deficiency. P1 and P3 have specific 
polysaccharide antibody deficiency. Results are pending for P2. All 
receive prophylactic antibiotics. P1 is treated with subcutaneous 
immunoglobulin substitution.
Conclusion
RTS is a genodermatosis with variable clinical presentation and 
course. Our observation of severe bone abnormalities and associated 
immunodeficiency merits attention for optimal management of 
these patients.
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Introduction
Chronic granulomatous disease is a primary immunodeficiency 
disorder characterized by recurrent life-threatening bacterial and 
fungal infections and granuloma formation. CGD is caused by 
